SCHEMBL4187429

SCHEMBL4187429

CCN(CCN(C1CC1)S(=O)(=O)c1ccc(OC)c(OC)c1)S(=O)(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ DRD2 P14416 1/20 0.49
▸ ADRA1D P25100 1/20 0.49
▸ ADRA1A P35348 1/20 0.49
▸ ADRA1B P35368 1/20 0.49
▸ HIF1A Q16665 5/20 0.48
▸ EPAS1 Q99814 4/20 0.48
▸ EP300 Q09472 1/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ PDE4A P27815 3/20 0.47
▸ PDE4B Q07343 3/20 0.47
▸ PDE4C Q08493 3/20 0.47
▸ PDE4D Q08499 3/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4177072 0.87 ALDH1A1 (0.68) TSHRHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL4191273 0.85 TSHR (0.52) TSHRHTTSMN1; SMN2TDP1ALDH1A1
SCHEMBL4176989 0.83 TSHR (0.50) TSHRHTTSMN1; SMN2TDP1ALDH1A1
SCHEMBL7204676 0.81 ALDH1A1 (0.77) TSHRHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL4184689 0.80 KMT2A (0.55) TSHRHTTSMN1; SMN2TDP1ALDH1A1
SCHEMBL5805522 0.78 ALDH1A1 (0.59) TSHRHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL13287135 0.78 ALDH1A1 (0.56) TSHRSMN1; SMN2ALDH1A1MAPTMAPK1
SCHEMBL16253501 0.77 ALDH1A1 (0.54) TSHRHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL7206100 0.76 L3MBTL1 (0.76) TSHRHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL5807986 0.75 HTR7 (0.54) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A TSHR 576/4885HTT 935/4885SMN1; SMN2 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback